Targeting the Hippo/YAP1 signaling pathway in hepatocellular carcinoma: From mechanisms to therapeutic drugs (Review)
- Authors:
- Shenghao Li
- Liyuan Hao
- Na Li
- Xiaoyu Hu
- Huimin Yan
- Erhei Dai
- Xinli Shi
-
Affiliations: Clinical Medical College, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, P.R. China, Department of Infectious Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 610072, P.R. China, Clinical Research Center, Shijiazhuang Fifth Hospital, Shijiazhuang, Hebei 050024, P.R. China, Center of Experimental Management, Shanxi University of Chinese Medicine, Jinzhong, Shanxi 030619, P.R. China - Published online on: July 31, 2024 https://doi.org/10.3892/ijo.2024.5676
- Article Number: 88
-
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang S and Zhou D: Role of the transcriptional coactivators YAP/TAZ in liver cancer. Curr Opin Cell Biol. 61:64–71. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Baecker A, Liu X, La Vecchia C and Zhang ZF: Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors. Eur J Cancer Prev. 27:205–212. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Nguyen-Lefebvre AT, Selzner N, Wrana JL and Bhat M: The hippo pathway: A master regulator of liver metabolism, regeneration, and disease. FASEB J. 35:e215702021. View Article : Google Scholar : PubMed/NCBI | |
|
Justice RW, Zilian O, Woods DF, Noll M and Bryant PJ: The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev. 9:534–546. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Tapon N, Harvey KF, Bell DW, Wahrer DC, Schiripo TA, Haber D and Hariharan IK: Salvador promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell. 110:467–478. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Jia J, Zhang W, Wang B, Trinko R and Jiang J: The Drosophila Ste20 family kinase dMST functions as a tumor suppressor by restricting cell proliferation and promoting apoptosis. Genes Dev. 17:2514–2519. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Fu M, Hu Y, Lan T, Guan KL, Luo T and Luo M: The Hippo signalling pathway and its implications in human health and diseases. Signal Transduct Target Ther. 7:3762022. View Article : Google Scholar : PubMed/NCBI | |
|
Hong AW, Meng Z and Guan KL: The Hippo pathway in intestinal regeneration and disease. Nat Rev Gastroenterol Hepatol. 13:324–337. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yao F, Xiao Z, Sun Y and Ma L: SKP2 and OTUD1 govern non-proteolytic ubiquitination of YAP that promotes YAP nuclear localization and activity. Cell Stress. 2:233–235. 2018. View Article : Google Scholar | |
|
Yu W, Qiao Y, Tang X, Ma L, Wang Y, Zhang X, Weng W, Pan Q, Yu Y, Sun F and Wang J: Tumor suppressor long non-coding RNA, MT1DP is negatively regulated by YAP and Runx2 to inhibit FoxA1 in liver cancer cells. Cell Signal. 26:2961–2968. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lai D, Ho KC, Hao Y and Yang X: Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res. 71:2728–2738. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
d'Angelo M, Benedetti E, Tupone MG, Catanesi M, Castelli V, Antonosante A and Cimini A: The role of stiffness in cell reprogramming: A potential role for biomaterials in inducing tissue regeneration. Cells. 8:10362019. View Article : Google Scholar : PubMed/NCBI | |
|
Song H, Mak KK, Topol L, Yun K, Hu J, Garrett L, Chen Y, Park O, Chang J, Simpson RM, et al: Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci USA. 107:1431–1436. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zanconato F, Cordenonsi M and Piccolo S: YAP/TAZ at the roots of cancer. Cancer Cell. 29:783–803. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Wang X and Yang Y: Hepatic Hippo signaling inhibits development of hepatocellular carcinoma. Clin Mol Hepatol. 26:742–750. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang C, Zhu ZM, Liu CL, He XJ, Feng XB, Zhang L, Dong JH and Zhang I HY: Yes-associated protein in hepatocellular carcinoma is associated with tumor differentiation and patient age at diagnosis, but not markers of HBV infection. Clin Lab. 62:365–371. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hu Y, Shin DJ, Pan H, Lin Z, Dreyfuss JM, Camargo FD, Miao J and Biddinger SB: YAP suppresses gluconeogenic gene expression through PGC1α. Hepatology. 66:2029–2041. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lee YA, Noon LA, Akat KM, Ybanez MD, Lee TF, Berres ML, Fujiwara N, Goossens N, Chou HI, Parvin-Nejad FP, et al: Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. Nat Commun. 9:49622018. View Article : Google Scholar : PubMed/NCBI | |
|
He L, Yuan L, Yu W, Sun Y, Jiang D, Wang X, Feng X, Wang Z, Xu J, Yang R, et al: A regulation loop between YAP and NR4A1 balances cell proliferation and apoptosis. Cell Rep. 33:1082842020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang C, Zhang L, He Q, Feng X, Zhu J, Xu Z, Wang X, Chen F, Li X and Dong J: Differences in yes-associated protein and mRNA levels in regenerating liver and hepatocellular carcinoma. Mol Med Rep. 5:410–414. 2012. | |
|
Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, Lowe SW, Poon RT and Luk JM: Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 115:4576–4585. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
LaQuaglia MJ, Grijalva JL, Mueller KA, Perez-Atayde AR, Kim HB, Sadri-Vakili G and Vakili K: YAP subcellular localization and hippo pathway transcriptome analysis in pediatric hepatocellular carcinoma. Sci Rep. 6:302382016. View Article : Google Scholar : PubMed/NCBI | |
|
Fitamant J, Kottakis F, Benhamouche S, Tian HS, Chuvin N, Parachoniak CA, Nagle JM, Perera RM, Lapouge M, Deshpande V, et al: YAP inhibition restores hepatocyte differentiation in advanced HCC, leading to tumor regression. Cell Rep. 10:1692–1707. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wu H, Liu Y, Jiang XW, Li WF, Guo G, Gong JP and Ding X: Clinicopathological and prognostic significance of yesassociated protein expression in hepatocellular carcinoma and hepatic cholangiocarcinoma. Tumour Biol. 37:13499–13508. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kim GJ, Kim H and Park YN: Increased expression of yes-associated protein 1 in hepatocellular carcinoma with stemness and combined hepatocellular-cholangiocarcinoma. PLoS One. 8:e754492013. View Article : Google Scholar : PubMed/NCBI | |
|
Perra A, Kowalik MA, Ghiso E, Ledda-Columbano GM, Di Tommaso L, Angioni MM, Raschioni C, Testore E, Roncalli M, Giordano S and Columbano A: YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol. 61:1088–1096. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Marquard S, Thomann S, Weiler SME, Bissinger M, Lutz T, Sticht C, Tóth M, de la Torre C, Gretz N, Straub BK, et al: Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator Inhibitor-1 (PAI-1) expression in hepatocarcinogenesis. Cell Commun Signal. 18:1662020. View Article : Google Scholar : PubMed/NCBI | |
|
Li H, Wang S, Wang G, Zhang Z, Wu X, Zhang T, Fu B and Chen G: Yes-associated protein expression is a predictive marker for recurrence of hepatocellular carcinoma after liver transplantation. Dig Surg. 31:468–478. 2014. View Article : Google Scholar | |
|
Gao Y, Gong Y, Liu Y, Xue Y, Zheng K, Guo Y, Hao L, Peng Q and Shi X: Integrated analysis of transcriptomics and metabolomics in human hepatocellular carcinoma HepG2215 cells after YAP1 knockdown. Acta Histochem. 125:1519872023. View Article : Google Scholar | |
|
Fan Y, Gao Y, Rao J, Wang K, Zhang F and Zhang C: YAP-1 promotes tregs differentiation in hepatocellular carcinoma by enhancing TGFBR2 transcription. Cell Physiol Biochem. 41:1189–1198. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Huo X, Zhang Q, Liu AM, Tang C, Gong Y, Bian J, Luk JM, Xu Z and Chen J: Overexpression of yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma. Oncol Rep. 29:840–846. 2013. View Article : Google Scholar | |
|
Gurda GT, Zhu Q, Bai H, Pan D, Schwarz KB and Anders RA: The use of yes-associated protein expression in the diagnosis of persistent neonatal cholestatic liver disease. Hum Pathol. 45:1057–1064. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lee K, Lee KB, Jung HY, Yi NJ, Lee KW, Suh KS and Jang JJ: The correlation between poor prognosis and increased yes-associated protein 1 expression in keratin 19 expressing hepatocellular carcinomas and cholangiocarcinomas. BMC Cancer. 17:4412017. View Article : Google Scholar : PubMed/NCBI | |
|
Smith JL, Rodríguez TC, Mou H, Kwan SY, Pratt H, Zhang XO, Cao Y, Liang S, Ozata DM, Yu T, et al: YAP1 withdrawal in hepatoblastoma drives therapeutic differentiation of tumor cells to functional hepatocyte-like cells. Hepatology. 73:1011–1027. 2021. View Article : Google Scholar | |
|
Gong W, Han Z, Fang F and Chen L: Yap expression is closely related to tumor angiogenesis and poor prognosis in hepatoblastoma. Fetal Pediatr Pathol. 41:929–939. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Kim MK, Park JY and Kang YN: Tumorigenic role of YAP in hepatocellular carcinogenesis is involved in SHP2 whose function is different in vitro and in vivo. Pathol Res Pract. 214:1031–1039. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Zhuo S, Zhou Y, Ma L, Sun Z, Wu X, Wang XW, Gao B and Yang Y: Yap-Sox9 signaling determines hepatocyte plasticity and lineage-specific hepatocarcinogenesis. J Hepatol. 76:652–664. 2022. View Article : Google Scholar : | |
|
Wei T, Weiler SME, Tóth M, Sticht C, Lutz T, Thomann S, De La Torre C, Straub B, Merker S, Ruppert T, et al: YAP-dependent induction of UHMK1 supports nuclear enrichment of the oncogene MYBL2 and proliferation in liver cancer cells. Oncogene. 38:5541–5550. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Jeric I, Maurer G, Cavallo AL, Raguz J, Desideri E, Tarkowski B, Parrini M, Fischer I, Zatloukal K and Baccarini M: A cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesis. Nat Commun. 7:137812016. View Article : Google Scholar : PubMed/NCBI | |
|
Badr EA, El Tantawy El Sayed I, Assar MF, Ali SA and Ibrahim NS: A pilot study of Livin gene and yes-associated protein 1 expression in hepatocellular carcinoma patients. Heliyon. 5:e027982019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Ma L, Weng W, Qiao Y, Zhang Y, He J, Wang H, Xiao W, Li L, Chu Q, et al: Mutual interaction between YAP and CREB promotes tumorigenesis in liver cancer. Hepatology. 58:1011–1020. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Xu G, Wang Y, Li W, Cao Y, Xu J, Hu Z, Hao Y, Hu L and Sun Y: COX-2 forms regulatory loop with YAP to promote proliferation and tumorigenesis of hepatocellular carcinoma cells. Neoplasia. 20:324–334. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Wang H, Zhang Y, Zhen N, Zhang L, Qiao Y, Weng W, Liu X, Ma L, Xiao W, et al: Mutual inhibition between YAP and SRSF1 maintains long non-coding RNA, Malat1-induced tumourigenesis in liver cancer. Cell Signal. 26:1048–1059. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Qiao K, Liu Y, Xu Z, Zhang H, Zhang H, Zhang C, Chang Z, Lu X, Li Z, Luo C, et al: RNA m6A methylation promotes the formation of vasculogenic mimicry in hepatocellular carcinoma via Hippo pathway. Angiogenesis. 24:83–96. 2021. View Article : Google Scholar | |
|
Sweed D, Abd-Elbary A, Sweed E, Mosbeh A, Moaz I, Yassein T and Elmashad S: Expression of cyclo-oxygenase-2 and yap/taz in hepatocellular carcinoma in untreated and treated hepatitis C virus patients. Pol J Pathol. 73:88–98. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Van Haele M, Moya IM, Karaman R, Rens G, Snoeck J, Govaere O, Nevens F, Verslype C, Topal B, Monbaliu D, et al: YAP and TAZ heterogeneity in primary liver cancer: An analysis of its prognostic and diagnostic role. Int J Mol Sci. 20:6382019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Wang J, Zhang S, Jia J, Liu X, Zhang J, Wang P, Song X, Che L, Liu K, et al: Distinct and overlapping roles of hippo effectors YAP and TAZ during human and mouse hepatocarcinogenesis. Cell Mol Gastroenterol Hepatol. 11:1095–1117. 2021. View Article : Google Scholar : | |
|
Moya IM, Castaldo SA, Van den Mooter L, Soheily S, Sansores-Garcia L, Jacobs J, Mannaerts I, Xie J, Verboven E, Hillen H, et al: Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice. Science. 366:1029–1034. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu YP, Pan LL and Kong CC: Stathmin 1 promotes the progression of liver cancer through interacting with YAP1. Eur Rev Med Pharmacol Sci. 24:7335–7344. 2020.PubMed/NCBI | |
|
Miao HL, Pan ZJ, Lei CJ, Wen JY, Li MY, Liu ZK, Qiu ZD, Lin MZ, Chen NP and Chen M: Knockdown of GPC3 inhibits the proliferation of Huh7 hepatocellular carcinoma cells through down-regulation of YAP. J Cell Biochem. 114:625–631. 2013. View Article : Google Scholar | |
|
Yang XM, Cao XY, He P, Li J, Feng MX, Zhang YL, Zhang XL, Wang YH, Yang Q, Zhu L, et al: Overexpression of Rac GTPase activating protein 1 contributes to proliferation of cancer cells by reducing Hippo signaling to promote cytokinesis. Gastroenterology. 155:1233–1249.e22. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Miao X and Zhang N: Role of RBM3 in the regulation of cell proliferation in hepatocellular carcinoma. Exp Mol Pathol. 117:1045462020. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan T, Zhou T, Qian M, Du J, Liu Y, Wang J, Li Y, Fan G, Yan F, Dai X, et al: SDHA/B reduction promotes hepatocellular carcinoma by facilitating the deNEDDylation of cullin1 and stabilizing YAP/TAZ. Hepatology. 78:103–119. 2023. View Article : Google Scholar | |
|
Zhang H, Liu H and Bi H: MicroRNA-345 inhibits hepatocellular carcinoma metastasis by inhibiting YAP1. Oncol Rep. 38:843–849. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang S, Li H, Wang G, Zhang T, Fu B, Ma M, Quan Z and Chen G: Yes-associated protein (YAP) expression is involved in epithelial-mesenchymal transition in hepatocellular carcinoma. Clin Transl Oncol. 18:172–177. 2016. View Article : Google Scholar | |
|
Shi C, Cai Y, Li Y, Li Y, Hu N, Ma S, Hu S, Zhu P, Wang W and Zhou H: Yap promotes hepatocellular carcinoma metastasis and mobilization via governing cofilin/F-actin/lamellipodium axis by regulation of JNK/Bnip3/SERCA/CaMKII pathways. Redox Biol. 14:59–71. 2018. View Article : Google Scholar | |
|
Wu D, Liu G, Liu Y, Saiyin H, Wang C, Wei Z, Zen W, Liu D, Chen Q, Zhao Z, et al: Zinc finger protein 191 inhibits hepatocellular carcinoma metastasis through discs large 1-mediated yes-associated protein inactivation. Hepatology. 64:1148–1162. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Weiler SME, Lutz T, Bissinger M, Sticht C, Knaub M, Gretz N, Schirmacher P and Breuhahn K: TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells. Cancer Lett. 473:164–175. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Tang Y, Thiess L, Weiler SME, Tóth M, Rose F, Merker S, Ruppert T, Schirmacher P and Breuhahn K: α-Catenin interaction with YAP/FoxM1/TEAD-induced CEP55 supports liver cancer cell migration. Cell Commun Signal. 21:1622023. View Article : Google Scholar | |
|
Fan Y, Du Z, Ding Q, Zhang J, Op Den Winkel M, Gerbes AL, Liu M and Steib CJ: SEPT6 drives hepatocellular carcinoma cell proliferation, migration and invasion via the Hippo/YAP signaling pathway. Int J Oncol. 58:132021. View Article : Google Scholar | |
|
Sun T, Mao W, Peng H, Wang Q and Jiao L: YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin. Cell Oncol (Dordr). 44:689–699. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Chen CL, Tsukamoto H, Liu JC, Kashiwabara C, Feldman D, Sher L, Dooley S, French SW, Mishra L, Petrovic L, et al: Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells. J Clin Invest. 123:2832–2849. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hayashi H, Higashi T, Yokoyama N, Kaida T, Sakamoto K, Fukushima Y, Ishimoto T, Kuroki H, Nitta H, Hashimoto D, et al: An imbalance in TAZ and YAP expression in hepatocellular carcinoma confers cancer stem cell-like behaviors contributing to disease progression. Cancer Res. 75:4985–4997. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Gao R, Kalathur RKR, Coto-Llerena M, Ercan C, Buechel D, Shuang S, Piscuoglio S, Dill MT, Camargo FD, Christofori G and Tang F: YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis. EMBO Mol Med. 13:e143512021. View Article : Google Scholar : PubMed/NCBI | |
|
Yang D, Jiao Y, Li Y and Fang X: Clinical characteristics and prognostic value of MEX3A mRNA in liver cancer. PeerJ. 8:e82522020. View Article : Google Scholar : PubMed/NCBI | |
|
Fang S, Zheng L, Chen X, Guo X, Ding Y, Ma J, Ding J, Chen W, Yang Y, Chen M, et al: MEX3A determines in vivo hepatocellular carcinoma progression and induces resistance to sorafenib in a Hippo-dependent way. Hepatol Int. 17:1500–1518. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Du H, Yang X, Fan J and Du X: Claudin 6: Therapeutic prospects for tumours, and mechanisms of expression and regulation (Review). Mol Med Rep. 24:6772021. View Article : Google Scholar : PubMed/NCBI | |
|
Kong FE, Li GM, Tang YQ, Xi SY, Loong JHC, Li MM, Li HL, Cheng W, Zhu WJ, Mo JQ, et al: Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate. Sci Transl Med. 13:eabb62822021. View Article : Google Scholar : PubMed/NCBI | |
|
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Di Benedetto G, Parisi S, Russo T and Passaro F: YAP and TAZ mediators at the crossroad between metabolic and cellular reprogramming. Metabolites. 11:1542021. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Q, Li J, Zhang W, Xiao C, Zhang S, Nian C, Li J, Su D, Chen L, Zhao Q, et al: Glycogen accumulation and phase separation drives liver tumor initiation. Cell. 184:5559–5576.e19. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Sun L, Suo C, Zhang T, Shen S, Gu X, Qiu S, Zhang P, Wei H, Ma W, Yan R, et al: ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism. Nat Chem Biol. 19:1492–1503. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Chen R, Zhu S, Fan XG, Wang H, Lotze MT, Zeh HJ III, Billiar TR, Kang R and Tang D: High mobility group protein B1 controls liver cancer initiation through yes-associated protein-dependent aerobic glycolysis. Hepatology. 67:1823–1841. 2018. View Article : Google Scholar | |
|
Athavale D, Song Z, Desert R, Han H, Das S, Ge X, Komakula SSB, Chen W, Gao S, Lantvit D, et al: Ablation of high-mobility group box-1 in the liver reduces hepatocellular carcinoma but causes hyperbilirubinemia in Hippo signaling-deficient mice. Hepatol Commun. 6:2155–2169. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Cox AG, Hwang KL, Brown KK, Evason K, Beltz S, Tsomides A, O'Connor K, Galli GG, Yimlamai D, Chhangawala S, et al: Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth. Nat Cell Biol. 18:886–896. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Park YY, Sohn BH, Johnson RL, Kang MH, Kim SB, Shim JJ, Mangala LS, Kim JH, Yoo JE, Rodriguez-Aguayo C, et al: Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. Hepatology. 63:159–172. 2016. View Article : Google Scholar | |
|
Anakk S, Bhosale M, Schmidt VA, Johnson RL, Finegold MJ and Moore DD: Bile acids activate YAP to promote liver carcinogenesis. Cell Rep. 5:1060–1069. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Delgado ER, Erickson HL, Tao J, Monga SP, Duncan AW and Anakk S: Scaffolding protein IQGAP1 is dispensable, but its overexpression promotes hepatocellular carcinoma via YAP1 signaling. Mol Cell Biol. 41:e00596–20. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Li K, Zhang J, Lyu H, Yang J, Wei W, Wang Y, Luo H, Zhang Y, Jiang X, Yi H, et al: CSN6-SPOP-HMGCS1 axis promotes hepatocellular carcinoma progression via YAP1 activation. Adv Sci (Weinh). 2:e23068272024. View Article : Google Scholar | |
|
Petty AJ and Yang Y: Tumor-associated macrophages: Implications in cancer immunotherapy. Immunotherapy. 9:289–302. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Li Z, Wu T, Zheng B and Chen L: Individualized precision treatment: Targeting TAM in HCC. Cancer Lett. 458:86–91. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Pu J, Xu Z, Nian J, Fang Q, Yang M, Huang Y, Li W, Ge B, Wang J and Wei H: M2 macrophage-derived extracellular vesicles facilitate CD8+T cell exhaustion in hepatocellular carcinoma via the miR-21-5p/YOD1/YAP/β-catenin pathway. Cell Death Discov. 7:1822021. View Article : Google Scholar | |
|
Xu X, Wang B, Liu Y, Jing T, Xu G, Zhang L, Jiao K, Chen Z, Xiang L, Xu C, et al: ETV4 potentiates nuclear YAP retention and activities to enhance the progression of hepatocellular carcinoma. Cancer Lett. 537:2156402022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao X, Wang X, You Y, Wen D, Feng Z, Zhou Y, Que K, Gong J and Liu Z: Nogo-B fosters HCC progression by enhancing Yap/Taz-mediated tumor-associated macrophages M2 polarization. Exp Cell Res. 391:1119792020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou TY, Zhou YL, Qian MJ, Fang YZ, Ye S, Xin WX, Yang XC and Wu HH: Interleukin-6 induced by YAP in hepatocellular carcinoma cells recruits tumor-associated macrophages. J Pharmacol Sci. 138:89–95. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Guo X, Zhao Y, Yan H, Yang Y, Shen S, Dai X, Ji X, Ji F, Gong XG, Li L, et al: Single tumor-initiating cells evade immune clearance by recruiting type II macrophages. Genes Dev. 31:247–259. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Y, Zheng S, Guo Q, Wei N, Xiao Z and Song Y: Upregulation of RACGAP1 is correlated with poor prognosis and immune infiltration in hepatocellular carcinoma. Transl Cancer Res. 13:847–863. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Desideri E, Castelli S, Dorard C, Toifl S, Grazi GL, Ciriolo MR and Baccarini M: Impaired degradation of YAP1 and IL6ST by chaperone-mediated autophagy promotes proliferation and migration of normal and hepatocellular carcinoma cells. Autophagy. 19:152–162. 2023. View Article : Google Scholar : | |
|
Lefort S, Joffre C, Kieffer Y, Givel AM, Bourachot B, Zago G, Bieche I, Dubois T, Meseure D, Vincent-Salomon A, et al: Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers. Autophagy. 10:2122–2142. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wang CZ, Yan GX, Dong DS, Xin H and Liu ZY: LncRNA-ATB promotes autophagy by activating yes-associated protein and inducing autophagy-related protein 5 expression in hepatocellular carcinoma. World J Gastroenterol. 25:5310–5322. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Zhu Z, Han L, Zhao L, Weng J, Yang H, Wu S, Chen K, Wu L and Chen T: A curcumin derivative, WZ35, suppresses hepatocellular cancer cell growth via downregulating YAP-mediated autophagy. Food Funct. 10:3748–3757. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Gao Y, Peng Q, Li S, Zheng K, Gong Y, Xue Y, Liu Y, Lu J, Zhang Y and Shi X: YAP1 suppression inhibits autophagy and improves the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma. Exp Cell Res. 424:1134862023. View Article : Google Scholar : PubMed/NCBI | |
|
Yan Z, Guo D, Tao R, Yu X, Zhang J, He Y, Zhang J, Li J, Zhang S and Guo W: Fluid shear stress induces cell migration via RhoA-YAP1-autophagy pathway in liver cancer stem cells. Cell Adh Migr. 16:94–106. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Carter SL, Eklund AC, Kohane IS, Harris LN and Szallasi Z: A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet. 38:1043–1048. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Weiler SME, Pinna F, Wolf T, Lutz T, Geldiyev A, Sticht C, Knaub M, Thomann S, Bissinger M, Wan S, et al: Induction of chromosome instability by activation of yes-associated protein and forkhead box M1 in liver cancer. Gastroenterology. 152:2037–2051.e22. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang S, Chen Q, Liu Q, Li Y, Sun X, Hong L, Ji S, Liu C, Geng J, Zhang W, et al: Hippo signaling suppresses cell ploidy and tumorigenesis through Skp2. Cancer Cell. 31:669–684.e7. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Li W, Dai Y, Shi B, Yue F, Zou J, Xu G, Jiang X, Wang F, Zhou X and Liu L: LRPPRC sustains Yap-P27-mediated cell ploidy and P62-HDAC6-mediated autophagy maturation and suppresses genome instability and hepatocellular carcinomas. Oncogene. 39:3879–3892. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Sun F, Qiao Y, Zheng W, Liu Y, Chen Y, Wu Q, Liu X, Zhu G, Chen Y, et al: TFCP2 is required for YAP-dependent transcription to stimulate liver malignancy. Cell Rep. 21:1227–1239. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Liu S, Zhai M, Xiao W, Zhou Q, Zhang D, Gong Y, Deng C, Liu C, Li L and He C: Intra-platelet serotonin and YAP contributed to poor prognosis of hepatocellular carcinoma. Life Sci. 270:1191402021. View Article : Google Scholar : PubMed/NCBI | |
|
Shu B, Zhai M, Miao X, He C, Deng C, Fang Y, Luo M, Liu L and Liu S: Serotonin and YAP/VGLL4 balance correlated with progression and poor prognosis of hepatocellular carcinoma. Sci Rep. 8:97392018. View Article : Google Scholar : PubMed/NCBI | |
|
Sinha S, Aizawa S, Nakano Y, Rialdi A, Choi HY, Shrestha R, Pan SQ, Chen Y, Li M, Kapelanski-Lamoureux A, et al: Hepatic stellate cell stearoyl co-A desaturase activates leukotriene B4 receptor 2-β-catenin cascade to promote liver tumorigenesis. Nat Commun. 14:26512023. View Article : Google Scholar | |
|
Chen J, Zhang J, Tian W, Ge C, Su Y, Li J and Tian H: AKR1C3 suppresses ferroptosis in hepatocellular carcinoma through regulation of YAP/SLC7A11 signaling pathway. Mol Carcinog. 62:833–844. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Jin Y, Yang R, Ding J, Zhu F, Zhu C, Xu Q and Cai J: KAT6A is associated with sorafenib resistance and contributes to progression of hepatocellular carcinoma by targeting YAP. Biochem Biophys Res Commun. 585:185–190. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Hata S, Hirayama J, Kajiho H, Nakagawa K, Hata Y, Katada T, Furutani-Seiki M and Nishina H: A novel acetylation cycle of transcription co-activator yes-associated protein that is downstream of Hippo pathway is triggered in response to SN2 alkylating agents. J Biol Chem. 287:22089–22098. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Tang X, Weng W, Qiao Y, Lin J, Liu W, Liu R, Ma L, Yu W, Yu Y, et al: The membrane protein melanoma cell adhesion molecule (MCAM) is a novel tumor marker that stimulates tumorigenesis in hepatocellular carcinoma. Oncogene. 34:5781–5795. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Cui R, Zhang X, Qiao Y, Liu X, Chang Y, Yu Y, Sun F and Wang J: SIRT1 increases YAP- and MKK3-dependent p38 phosphorylation in mouse liver and human hepatocellular carcinoma. Oncotarget. 7:11284–11298. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Mao B, Hu F, Cheng J, Wang P, Xu M, Yuan F, Meng S, Wang Y, Yuan Z and Bi W: SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma. Oncogene. 33:1468–1474. 2014. View Article : Google Scholar | |
|
Wu J, Chai H, Li F, Ren Q and Gu Y: SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma. Life Sci. 260:1184062020. View Article : Google Scholar : PubMed/NCBI | |
|
Chen S, Wu H, Wang Z, Jia M, Guo J, Jin J, Li X, Meng D, Lin L, He AR, et al: Loss of SPTBN1 suppresses autophagy Via SETD7-mediated YAP methylation in hepatocellular carcinoma initiation and development. Cell Mol Gastroenterol Hepatol. 13:949–973.e7. 2022. View Article : Google Scholar : | |
|
Xu B, Li SH, Zheng R, Gao SB, Ding LH, Yin ZY, Lin X, Feng ZJ, Zhang S, Wang XM and Jin GH: Menin promotes hepatocellular carcinogenesis and epigenetically up-regulates Yap1 transcription. Proc Natl Acad Sci USA. 110:17480–17485. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wu BK, Mei SC, Chen EH, Zheng Y and Pan D: YAP induces an oncogenic transcriptional program through TET1-mediated epigenetic remodeling in liver growth and tumorigenesis. Nat Genet. 54:1202–1213. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Dong X, Zhang X, Liu P, Tian Y, Li L and Gong P: Lipolysis-stimulated lipoprotein receptor impairs hepatocellular carcinoma and inhibits the oncogenic activity of YAP1 via PPPY motif. Front Oncol. 12:8964122022. View Article : Google Scholar : PubMed/NCBI | |
|
Jeon Y, Yoo JE, Rhee H, Kim YJ, Il Kim G, Chung T, Yoon S, Shin B, Woo HG and Park YN: YAP inactivation in estrogen receptor alpha-positive hepatocellular carcinoma with less aggressive behavior. Exp Mol Med. 53:1055–1067. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Qiao Y, Wu Q, Chen Y, Zou S, Liu X, Zhu G, Zhao Y, Chen Y, Yu Y, et al: The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis. Nat Commun. 8:152802017. View Article : Google Scholar : PubMed/NCBI | |
|
Simile MM, Latte G, Demartis MI, Brozzetti S, Calvisi DF, Porcu A, Feo CF, Seddaiu MA, Daino L, Berasain C, et al: Post-translational deregulation of YAP1 is genetically controlled in rat liver cancer and determines the fate and stem-like behavior of the human disease. Oncotarget. 7:49194–49216. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Qiu Y, Huang D, Sheng Y, Huang J, Li N, Zhang S, Hong Z, Yin X and Yan J: Deubiquitinating enzyme USP46 suppresses the progression of hepatocellular carcinoma by stabilizing MST1. Exp Cell Res. 405:1126462021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu H, Yan F, Yuan T, Qian M, Zhou T, Dai X, Cao J, Ying M, Dong X, He Q and Yang B: USP10 promotes proliferation of hepatocellular carcinoma by deubiquitinating and stabilizing YAP/TAZ. Cancer Res. 80:2204–2216. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Tian Z, Xu C, He W, Lin Z, Zhang W, Tao K, Ding R, Zhang X and Dou K: The deubiquitinating enzyme USP19 facilitates hepatocellular carcinoma progression through stabilizing YAP. Cancer Lett. 577:2164392023. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang S, Xu Y, Xie C, Ren L, Wu G, Yang M, Wu X, Tang M, Hu Y, Li Z, et al: RNF219/α-catenin/LGALS3 axis promotes hepatocellular carcinoma bone metastasis and associated skeletal complications. Adv Sci (Weinh). 8:20019612020. View Article : Google Scholar | |
|
Wang J, Park JS, Wei Y, Rajurkar M, Cotton JL, Fan Q, Lewis BC, Ji H and Mao J: TRIB2 acts downstream of Wnt/TCF in liver cancer cells to regulate YAP and C/EBPα function. Mol Cell. 51:211–225. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Zhang X, Lin J, Chen Y, Qiao Y, Guo S, Yang Y, Zhu G, Pan Q, Wang J and Sun F: CCT3 acts upstream of YAP and TFCP2 as a potential target and tumour biomarker in liver cancer. Cell Death Dis. 10:6442019. View Article : Google Scholar : PubMed/NCBI | |
|
Tu K, Yang W, Li C, Zheng X, Lu Z, Guo C, Yao Y and Liu Q: Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma. Mol Cancer. 13:1102014. View Article : Google Scholar : PubMed/NCBI | |
|
Kim W, Khan SK, Gvozdenovic-Jeremic J, Kim Y, Dahlman J, Kim H, Park O, Ishitani T, Jho EH, Gao B and Yang Y: Hippo signaling interactions with Wnt/β-catenin and Notch signaling repress liver tumorigenesis. J Clin Invest. 127:137–152. 2017. View Article : Google Scholar | |
|
Conboy CB, Vélez-Reyes GL, Tschida BR, Hu H, Kaufmann G, Koes N, Keller B, Alsinet C, Cornellà H, Pinyol R, et al: R-spondin 2 drives liver tumor development in a yes-associated protein-dependent manner. Hepatol Commun. 3:1496–1509. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Min Q, Molina L, Li J, Adebayo Michael AO, Russell JO, Preziosi ME, Singh S, Poddar M, Matz-Soja M, Ranganathan S, et al: β-Catenin and yes-associated protein 1 cooperate in hepatoblastoma pathogenesis. Am J Pathol. 189:1091–1104. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Lu S, Jiang M, Chen Q, Luo X, Cao Z, Huang H, Zheng M and Du J: Upregulated YAP promotes oncogenic CTNNB1 expression contributing to molecular pathology of hepatoblastoma. Pediatr Blood Cancer. 69:e297052022. View Article : Google Scholar : PubMed/NCBI | |
|
Tao J, Calvisi DF, Ranganathan S, Cigliano A, Zhou L, Singh S, Jiang L, Fan B, Terracciano L, Armeanu-Ebinger S, et al: Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology. 147:690–701. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bisso A, Filipuzzi M, Gamarra Figueroa GP, Brumana G, Biagioni F, Doni M, Ceccotti G, Tanaskovic N, Morelli MJ, Pendino V, et al: Cooperation between MYC and β-catenin in liver tumorigenesis requires Yap/Taz. Hepatology. 72:1430–1443. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Yu H, Dong W, Zhang C, Hu M, Ma W, Jiang X, Li H, Yang P and Xiang D: N6-methyladenosine-mediated up-regulation of FZD10 regulates liver cancer stem cells' properties and lenvatinib resistance through WNT/β-catenin and Hippo signaling pathways. Gastroenterology. 164:990–1005. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Xiang D, Zhu X, Zhang Y, Zou J, Li J, Kong L and Zhang H: Tribbles homolog 2 promotes hepatic fibrosis and hepatocarcinogenesis through phosphatase 1A-mediated stabilization of yes-associated protein. Liver Int. 41:1131–1147. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Q, Feng J and Tang L: Non-coding RNA related to MAPK signaling pathway in liver cancer. Int J Mol Sci. 23:119082022. View Article : Google Scholar : PubMed/NCBI | |
|
Li S, Dai M, Wang F, Hao L, Feng C, Jia Y, Li Y, Kang X, Hu X and Yan H: PD-1/PD-L1 interaction upregulates YAP1 expression in HepG2 cells through MAPK/ERK pathway. Nat Prod Commun. 18:1–12. 2023. | |
|
Li L, Wang J, Zhang Y, Zhang Y, Ma L, Weng W, Qiao Y, Xiao W, Wang H, Yu W, et al: MEK1 promotes YAP and their interaction is critical for tumorigenesis in liver cancer. FEBS Lett. 587:3921–3927. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Leung CON, Yang Y, Leung RWH, So KKH, Guo HJ, Lei MML, Muliawan GK, Gao Y, Yu QQ, Yun JP, et al: Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma. Nat Commun. 14:66992023. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Tao J, Cigliano A, Sini M, Calderaro J, Azoulay D, Wang C, Liu Y, Jiang L, Evert K, et al: Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver. Oncotarget. 6:10102–10115. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ma L, Wang J, Lin J, Pan Q, Yu Y and Sun F: Cluster of differentiation 166 (CD166) regulated by phosphatidylinositide 3-Kinase (PI3K)/AKT signaling to exert its anti-apoptotic role via yes-associated protein (YAP) in liver cancer. J Biol Chem. 289:6921–6933. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Fan Z, Xia H, Xu H, Ma J, Zhou S, Hou W, Tang Q, Gong Q, Nie Y and Bi F: Standard CD44 modulates YAP1 through a positive feedback loop in hepatocellular carcinoma. Biomed Pharmacother. 103:147–156. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Cho DC: Targeting the PI3K/Akt/mTOR pathway in malignancy: Rationale and clinical outlook. BioDrugs. 28:373–381. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang S, Zhou YF, Cao J, Burley SK, Wang HY and Zheng XFS: mTORC1 promotes ARID1A degradation and oncogenic chromatin remodeling in hepatocellular carcinoma. Cancer Res. 81:5652–5665. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Niu Q, Ye S, Zhao L, Qian Y and Liu F: The role of liver cancer stem cells in hepatocellular carcinoma metastasis. Cancer Biol Ther. 25:23217682024. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshida J, Ishikawa T, Endo Y, Matsumura S, Ota T, Mizushima K, Hirai Y, Oka K, Okayama T, Sakamoto N, et al: Metformin inhibits TGF-β1-induced epithelial-mesenchymal transition and liver metastasis of pancreatic cancer cells. Oncol Rep. 44:371–381. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ou H, Chen Z, Xiang L, Fang Y, Xu Y, Liu Q, Hu Z, Li X, Huang Y and Yang D: Frizzled 2-induced epithelial-mesenchymal transition correlates with vasculogenic mimicry, stemness, and Hippo signaling in hepatocellular carcinoma. Cancer Sci. 110:1169–1182. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sun B, Zhong FJ, Xu C, Li YM, Zhao YR, Cao MM and Yang LY: Programmed cell death 10 promotes metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma via PP2Ac-mediated YAP activation. Cell Death Dis. 12:8492021. View Article : Google Scholar : PubMed/NCBI | |
|
Hu H, Xu L, Luo SJ, Xiang T, Chen Y, Cao ZR, Zhang YJ, Mo Z, Wang Y, Meng DF, et al: Retinal dehydrogenase 5 (RHD5) attenuates metastasis via regulating HIPPO/YAP signaling pathway in hepatocellular carcinoma. Int J Med Sci. 17:1897–1908. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Xu M, Wang J, Xu Z, Li R, Wang P, Shang R, Cigliano A, Ribback S, Solinas A, Pes GM, et al: SNAI1 promotes the cholangiocellular phenotype, but not epithelial-mesenchymal transition, in a murine hepatocellular carcinoma model. Cancer Res. 79:5563–5574. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tschaharganeh DF, Chen X, Latzko P, Malz M, Gaida MM, Felix K, Ladu S, Singer S, Pinna F, Gretz N, et al: Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology. 144:1530–1542.e12. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Huang J, Zhang L, Wan D, Zhou L, Zheng S, Lin S and Qiao Y: Extracellular matrix and its therapeutic potential for cancer treatment. Signal Transduct Target Ther. 6:1532021. View Article : Google Scholar : PubMed/NCBI | |
|
Chakraborty S, Njah K, Pobbati AV, Lim YB, Raju A, Lakshmanan M, Tergaonkar V, Lim CT and Hong W: Agrin as a mechanotransduction signal regulating YAP through the Hippo pathway. Cell Rep. 18:2464–2479. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Xiong YX, Zhang XC, Zhu JH, Zhang YX, Pan YL, Wu Y, Zhao JP, Liu JJ, Lu YX, Liang HF, et al: Collagen I-DDR1 signaling promotes hepatocellular carcinoma cell stemness via Hippo signaling repression. Cell Death Differ. 30:1648–1665. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Xia H, Dai X, Yu H, Zhou S, Fan Z, Wei G, Tang Q, Gong Q and Bi F: EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: The mechanism and its implications in targeted therapy. Cell Death Dis. 9:2692018. View Article : Google Scholar : PubMed/NCBI | |
|
Meng Y, Zhao Q, An L, Jiao S, Li R, Sang Y, Liao J, Nie P, Wen F, Ju J, et al: A TNFR2-hnRNPK axis promotes primary liver cancer development via activation of YAP signaling in hepatic progenitor cells. Cancer Res. 81:3036–3050. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Ahmed MB, Alghamdi AAA, Islam SU, Lee JS and Lee YS: cAMP signaling in cancer: A PKA-CREB and EPAC-centric approach. Cells. 11:20202022. View Article : Google Scholar : PubMed/NCBI | |
|
Ren H, Chen Y, Ao Z, Cheng Q, Yang X, Tao H, Zhao L, Shen A, Li P and Fu Q: PDE4D binds and interacts with YAP to cooperatively promote HCC progression. Cancer Lett. 541:2157492022. View Article : Google Scholar : PubMed/NCBI | |
|
Hu CT, Wu JR, Cheng CC and Wu WS: The therapeutic targeting of HGF/c-Met signaling in hepatocellular carcinoma: Alternative approaches. Cancers (Basel). 9:582017. View Article : Google Scholar : PubMed/NCBI | |
|
He Q, Lin Z, Wang Z, Huang W, Tian D, Liu M and Xia L: SIX4 promotes hepatocellular carcinoma metastasis through upregulating YAP1 and c-MET. Oncogene. 39:7279–7295. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Xu C, Liu C, Huang W, Tu S and Wan F: Effect of Mst1 overexpression on the growth of human hepatocellular carcinoma HepG2 cells and the sensitivity to cisplatin in vitro. Acta Biochim Biophys Sin (Shanghai). 45:268–279. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, Lauwers GY, Thasler W, Lee JT, Avruch J and Bardeesy N: Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell. 16:425–438. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang J, Zheng Y, Chen F, Dong L and Guo X: Activation of YAP1 by STK25 contributes to the progression of hepatocellular carcinoma. Tissue Cell. 76:1017972022. View Article : Google Scholar : PubMed/NCBI | |
|
Wong KF, Liu AM, Hong W, Xu Z and Luk JM: Integrin α2β1 inhibits MST1 kinase phosphorylation and activates yes-associated protein oncogenic signaling in hepatocellular carcinoma. Oncotarget. 7:77683–77695. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Shu B, Zhou Y, Lei G, Peng Y, Ding C, Li Z and He C: TRIM21 is critical in regulating hepatocellular carcinoma growth and response to therapy by altering the MST1/YAP pathway. Cancer Sci. 115:1476–1491. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Gu Y, Ding C, Yu T, Liu B, Tang W, Wang Z, Tang X, Liang G, Peng J, Zhang X and Li Z: SIRT7 promotes Hippo/YAP activation and cancer cell proliferation in hepatocellular carcinoma via suppressing MST1. Cancer Sci. 115:1209–1223. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu J, Tang W, Fang P, Wang C, Gu M, Yang W, Pan B, Wang B and Guo W: STRN3 promotes tumour growth in hepatocellular carcinoma by inhibiting the hippo pathway. J Cell Mol Med. 28:e181472024. View Article : Google Scholar : PubMed/NCBI | |
|
Wang C, Zhu ZM, Liu CL, He XJ, Zhang HY and Dong JH: Knockdown of yes-associated protein inhibits proliferation and downregulates large tumor suppressor 1 expression in MHCC97H human hepatocellular carcinoma cells. Mol Med Rep. 11:4101–4108. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Guo C, Wang X and Liang L: LATS2-mediated YAP1 phosphorylation is involved in HCC tumorigenesis. Int J Clin Exp Pathol. 8:1690–1697. 2015.PubMed/NCBI | |
|
Xu W, Gong F, Zhang T, Chi B and Wang J: RNA-binding protein Dnd1 inhibits epithelial-mesenchymal transition and cancer stem cell-related traits on hepatocellular carcinoma cells. Biotechnol Lett. 39:1359–1367. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Fan Q, Li Y, Yang Z, Yang L, Zong Z, Wang B, Meng X, Li Q, Liu J and Li H: Transforming growth factor-beta1 suppresses hepatocellular carcinoma proliferation via activation of Hippo signaling. Oncotarget. 8:29785–29794. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Yan S, Chen J, Gan C, Chen D, Li Y, Wen J, Kremerskothen J, Chen S, Zhang J and Cao Y: WWC2 is an independent prognostic factor and prevents invasion via Hippo signalling in hepatocellular carcinoma. J Cell Mol Med. 21:3718–3729. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Huang Z, Zhou JK, Wang K, Chen H, Qin S, Liu J, Luo M, Chen Y, Jiang J, Zhou L, et al: PDLIM1 inhibits tumor metastasis through activating Hippo signaling in hepatocellular carcinoma. Hepatology. 71:1643–1659. 2020. View Article : Google Scholar | |
|
Chen Q, Zhou XW, Zhang AJ and He K: ACTN1 supports tumor growth by inhibiting Hippo signaling in hepatocellular carcinoma. J Exp Clin Cancer Res. 40:232021. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng Y, Hou T, Ping J, Chen T and Yin B: LMO3 promotes hepatocellular carcinoma invasion, metastasis and anoikis inhibition by directly interacting with LATS1 and suppressing Hippo signaling. J Exp Clin Cancer Res. 37:2282018. View Article : Google Scholar : PubMed/NCBI | |
|
Yan YC, Meng GX, Yang CC, Yang YF, Tan SY, Yan LJ, Ding ZN, Ma YL, Dong ZR and Li T: Diacylglycerol lipase alpha promotes hepatocellular carcinoma progression and induces lenvatinib resistance by enhancing YAP activity. Cell Death Dis. 14:4042023. View Article : Google Scholar | |
|
Jeong SH, Kim HB, Kim MC, Lee JM, Lee JH, Kim JH, Kim JW, Park WY, Kim SY, Kim JB, et al: Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer. J Clin Invest. 128:1010–1025. 2018. View Article : Google Scholar | |
|
Lee KP, Lee JH, Kim TS, Kim TH, Park HD, Byun JS, Kim MC, Jeong WI, Calvisi DF, Kim JM and Lim DS: The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci USA. 107:8248–8253. 2010. View Article : Google Scholar | |
|
Adler JJ, Johnson DE, Heller BL, Bringman LR, Ranahan WP, Conwell MD, Sun Y, Hudmon A and Wells CD: Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases. Proc Natl Acad Sci USA. 110:17368–17373. 2013. View Article : Google Scholar | |
|
Liu Y, Lu Z, Shi Y and Sun F: AMOT is required for YAP function in high glucose induced liver malignancy. Biochem Biophys Res Commun. 495:1555–1561. 2018. View Article : Google Scholar | |
|
Liu M, Jiang K, Lin G, Liu P, Yan Y, Ye T, Yao G, Barr MP, Liang D, Wang Y, et al: Ajuba inhibits hepatocellular carcinoma cell growth via targeting of β-catenin and YAP signaling and is regulated by E3 ligase Hakai through neddylation. J Exp Clin Cancer Res. 37:1652018. View Article : Google Scholar | |
|
Wang Y, Zhu Y, Gu Y, Ma M, Wang Y, Qi S, Zeng Y, Zhu R, Wang X, Yu P, et al: Stabilization of Motin family proteins in NF2-deficient cells prevents full activation of YAP/TAZ and rapid tumorigenesis. Cell Rep. 36:1095962021. View Article : Google Scholar : PubMed/NCBI | |
|
Yi C, Shen Z, Stemmer-Rachamimov A, Dawany N, Troutman S, Showe LC, Liu Q, Shimono A, Sudol M, Holmgren L, et al: The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis. Sci Signal. 6:ra772013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, Liu P, Tao J, Wang P, Zhang Y, Song X, Che L, Sumazin P, Ribback S, Kiss A, et al: TEA domain transcription factor 4 is the major mediator of yes-associated protein oncogenic activity in mouse and human hepatoblastoma. Am J Pathol. 189:1077–1090. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Luo W, Li Y, Zeng Y, Li Y, Cheng M, Zhang C, Li F, Wu Y, Huang C, Yang X, et al: Tea domain transcription factor TEAD4 mitigates TGF-β signaling and hepatocellular carcinoma progression independently of YAP. J Mol Cell Biol. 15:mjad0102023. View Article : Google Scholar | |
|
Cai WY, Lin LY, Hao H, Zhang SM, Ma F, Hong XX, Zhang H, Liu QF, Ye GD, Sun GB, et al: Yes-associated protein/TEA domain family member and hepatocyte nuclear factor 4-alpha (HNF4α) repress reciprocally to regulate hepatocarcinogenesis in rats and mice. Hepatology. 65:1206–1221. 2017. View Article : Google Scholar | |
|
Zhu C, Wei Y and Wei X: AXL receptor tyrosine kinase as a promising anti-cancer approach: Functions, molecular mechanisms and clinical applications. Mol Cancer. 18:1532019. View Article : Google Scholar : PubMed/NCBI | |
|
Xu MZ, Chan SW, Liu AM, Wong KF, Fan ST, Chen J, Poon RT, Zender L, Lowe SW, Hong W and Luk JM: AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene. 30:1229–1240. 2011. View Article : Google Scholar | |
|
Shen YW, Zhou YD, Chen HZ, Luan X and Zhang WD: Targeting CTGF in cancer: An emerging therapeutic opportunity. Trends Cancer. 7:511–524. 2021. View Article : Google Scholar | |
|
Cheng JC, Wang EY, Yi Y, Thakur A, Tsai SH and Hoodless PA: S1P stimulates proliferation by upregulating CTGF expression through S1PR2-mediated YAP activation. Mol Cancer Res. 16:1543–1555. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Dong Q, Fu L, Zhao Y, Xie C, Li Q and Wang E: TNFAIP8 interacts with LATS1 and promotes aggressiveness through regulation of Hippo pathway in hepatocellular carcinoma. Oncotarget. 8:15689–15703. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang C, Wei W, Tu S, Liang B, Li C, Li Y, Luo W, Wu Y, Dai X, Wang Y, et al: Upregulation of CYR61 by TGF-β and YAP signaling exerts a counter-suppression of hepatocellular carcinoma. J Biol Chem. 21:1072082024. View Article : Google Scholar | |
|
Ahn EY, Kim JS, Kim GJ and Park YN: RASSF1A-mediated regulation of AREG via the Hippo pathway in hepatocellular carcinoma. Mol Cancer Res. 11:748–758. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Sun X, Gao L, Chien HY, Li WC and Zhao J: The regulation and function of the NUAK family. J Mol Endocrinol. 51:R15–R22. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan WC, Pepe-Mooney B, Galli GG, Dill MT, Huang HT, Hao M, Wang Y, Liang H, Calogero RA and Camargo FD: NUAK2 is a critical YAP target in liver cancer. Nat Commun. 9:48342018. View Article : Google Scholar : PubMed/NCBI | |
|
Li S, Ji J, Zhang Z, Peng Q, Hao L, Guo Y, Zhou W, Cui Q and Shi X: Cisplatin promotes the expression level of PD-L1 in the microenvironment of hepatocellular carcinoma through YAP1. Mol Cell Biochem. 475:79–91. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, Liu JO and Pan D: Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 26:1300–1305. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Fu J, McGrath NA, Lee J, Wang X, Brar G and Xie C: Verteporfin synergizes the efficacy of anti-PD-1 in cholangiocarcinoma. Hepatobiliary Pancreat Dis Int. 21:485–492. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Quan Y, Li Z, Zhu K and Liang J: Transcatheter arterial chemoembolization combined with Hippo/YAP inhibition significantly improve the survival of rats with transplanted hepatocellular carcinoma. Lipids Health Dis. 20:742021. View Article : Google Scholar : PubMed/NCBI | |
|
Pinyopornpanish K, Al-Yaman W, Butler RS, Carey W, McCullough A and Romero-Marrero C: Chemopreventive effect of statin on hepatocellular carcinoma in patients with nonalcoholic steatohepatitis cirrhosis. Am J Gastroenterol. 116:2258–2269. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Benhammou JN, Qiao B, Ko A, Sinnett-Smith J, Pisegna JR and Rozengurt E: Lipophilic statins inhibit YAP coactivator transcriptional activity in HCC cells through Rho-mediated modulation of actin cytoskeleton. Am J Physiol Gastrointest Liver Physiol. 325:G239–G250. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Y, Zhang Y, Cao J, Su Z, Li F, Zhang P, Zhang B, Liu R, Zhang L, Xie J, et al: FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling. J Exp Clin Cancer Res. 42:962023. View Article : Google Scholar : PubMed/NCBI | |
|
Fukushima K, Takahashi K, Fukushima N, Honoki K and Tsujiuchi T: Different effects of GPR120 and GPR40 on cellular functions stimulated by 12-O-tetradecanoylphorbol-13-acetate in melanoma cells. Biochem Biophys Res Commun. 475:25–30. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu G, Chen Y, Zhang X, Wu Q, Zhao Y, Chen Y, Sun F, Qiao Y and Wang J: 12-O-Tetradecanoylphorbol-13-acetate (TPA) is anti-tumorigenic in liver cancer cells via inhibiting YAP through AMOT. Sci Rep. 7:449402017. View Article : Google Scholar : PubMed/NCBI | |
|
Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, et al: Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 379:753–763. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Jia Y, Jin H, Gao L, Yang X, Wang F, Ding H, Chen A, Tan S, Zhang F, Shao J, et al: A novel lncRNA PLK4 up-regulated by talazoparib represses hepatocellular carcinoma progression by promoting YAP-mediated cell senescence. J Cell Mol Med. 24:5304–5316. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Tataranni T and Piccoli C: Dichloroacetate (DCA) and cancer: An overview towards clinical applications. Oxid Med Cell Longev. 2019:82010792019. View Article : Google Scholar : PubMed/NCBI | |
|
Su D and Lin Z: Dichloroacetate attenuates the stemness of hepatocellular carcinoma cells via promoting nucleus-cytoplasm translocation of YAP. Environ Toxicol. 36:975–983. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G and Radue EW; FTY720 D2201 Study Group: Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 355:1124–1140. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Du J, Qian M, Yuan T, Zhang B, Chen X, An N, He Q, Yang B, Ye S and Zhu H: Fingolimod exerts in vitro anticancer activity against hepatocellular carcinoma cell lines via YAP/TAZ suppression. Acta Pharm. 72:427–436. 2022. View Article : Google Scholar | |
|
Zhao D, Xia L, Geng W, Xu D, Zhong C, Zhang J and Xia Q: Metformin suppresses interleukin-22 induced hepatocellular carcinoma by upregulating Hippo signaling pathway. J Gastroenterol Hepatol. 36:3469–3476. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Tian Y, Tang B, Wang C, Sun D, Zhang R, Luo N, Han Z, Liang R, Gao Z and Wang L: Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP. Oncotarget. 7:46230–46241. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, Dolcetti L, Bronte V and Borrello I: Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 203:2691–2702. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Kong D, Jiang Y, Miao X, Wu Z, Liu H and Gong W: Tadalafil enhances the therapeutic efficacy of BET inhibitors in hepatocellular carcinoma through activating Hippo pathway. Biochim Biophys Acta Mol Basis Dis. 1867:1662672021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhong Y, Qi H, Li X, An M, Shi Q and Qi J: Tumor supernatant derived from hepatocellular carcinoma cells treated with vincristine sulfate have therapeutic activity. Eur J Pharm Sci. 155:1055572020. View Article : Google Scholar : PubMed/NCBI | |
|
Wu L, Pang Y, Qin G, Xi G, Wu S, Wang X and Chen T: Farnesylthiosalicylic acid sensitizes hepatocarcinoma cells to artemisinin derivatives. PLoS One. 12:e01718402017. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Lu J, Chen Q, Han S, Shao H, Chen P, Jin Q, Yang M, Shangguan F, Fei M, et al: Artemisinin suppresses hepatocellular carcinoma cell growth, migration and invasion by targeting cellular bioenergetics and Hippo-YAP signaling. Arch Toxicol. 93:3367–3383. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hao L, Guo Y, Peng Q, Zhang Z, Ji J, Liu Y, Xue Y, Li C, Zheng K and Shi X: Dihydroartemisinin reduced lipid droplet deposition by YAP1 to promote the anti-PD-1 effect in hepatocellular carcinoma. Phytomedicine. 96:1539132022. View Article : Google Scholar : PubMed/NCBI | |
|
Peng Q, Hao L, Guo Y, Zhang Z, Ji J, Xue Y, Liu Y, Li C, Lu J and Shi X: Dihydroartemisinin inhibited the Warburg effect through YAP1/SLC2A1 pathway in hepatocellular carcinoma. J Nat Med. 77:28–40. 2023. View Article : Google Scholar | |
|
Guo Y, Peng Q, Hao L, Ji J, Zhang Z, Xue Y, Liu Y, Gao Y, Li C and Shi X: Dihydroartemisinin promoted FXR expression independent of YAP1 in hepatocellular carcinoma. FASEB J. 36:e223612022. View Article : Google Scholar : PubMed/NCBI | |
|
Gong Y, Peng Q, Gao Y, Yang J, Lu J, Zhang Y, Yang Y, Liang H, Yue Y and Shi X: Dihydroartemisinin inhibited interleukin-18 expression by decreasing YAP1 in hepatocellular carcinoma cells. Acta Histochem. 125:1520402023. View Article : Google Scholar : PubMed/NCBI | |
|
Peng Q, Li S, Shi X, Guo Y, Hao L, Zhang Z, Ji J, Zhao Y, Li C, Xue Y and Liu Y: Dihydroartemisinin broke the tumor immunosuppressive microenvironment by inhibiting YAP1 expression to enhance anti-PD-1 efficacy. Phytother Res. 37:1740–1753. 2023. View Article : Google Scholar | |
|
Zhang Z, Shi X, Ji J, Guo Y, Peng Q, Hao L, Xue Y, Liu Y, Li C, Lu J and Yu K: Dihydroartemisinin increased the abundance of Akkermansia muciniphila by YAP1 depression that sensitizes hepatocellular carcinoma to anti-PD-1 immunotherapy. Front Med. 17:729–746. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Wang H and Wang L, Tan R, Zhu M, Zhong X, Zhang Y, Chen B and Wang L: Decursin inhibits the growth of HepG2 hepatocellular carcinoma cells via Hippo/YAP signaling pathway. Phytother Res. 32:2456–2465. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Li M, Chen J, Yu X, Xu S, Li D, Zheng Q and Yin Y: Myricetin suppresses the propagation of hepatocellular carcinoma via down-regulating expression of YAP. Cells. 8:3582019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao S, Xu K, Jiang R, Li DY, Guo XX, Zhou P, Tang JF, Li LS, Zeng D, Hu L, et al: Evodiamine inhibits proliferation and promotes apoptosis of hepatocellular carcinoma cells via the Hippo-yes-associated protein signaling pathway. Life Sci. 251:1174242020. View Article : Google Scholar : PubMed/NCBI | |
|
Wu K, Teng M, Zhou W, Lu F, Zhou Y, Zeng J, Yang J, Liu X, Zhang Y, Ding Y and Shen W: Wogonin induces cell cycle arrest and apoptosis of hepatocellular carcinoma cells by activating Hippo signaling. Anticancer Agents Med Chem. 22:1551–1560. 2022. View Article : Google Scholar | |
|
Zhang J, Tong Y, Lu X, Dong F, Ma X, Yin S, He Y, Liu Y, Liu Q and Fan D: A derivant of ginsenoside CK and its inhibitory effect on hepatocellular carcinoma. Life Sci. 304:1206982022. View Article : Google Scholar : PubMed/NCBI | |
|
Zeng J, Xie H, Zhang ZL, Li ZX, Shi L, Wu KY, Zhou Y, Tian Z, Zhang Y, Zhou W and Shen WG: Apigenin regulates the migration, invasion, and autophagy of hepatocellular carcinoma cells by downregulating YAP. Neoplasma. 69:292–302. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Yun UJ, Bae SJ, Song YR and Kim YW: A critical YAP in malignancy of HCC is regulated by evodiamine. Int J Mol Sci. 23:18552022. View Article : Google Scholar : PubMed/NCBI | |
|
Chen YL, Yen IC, Lin KT, Lai FY and Lee SY: 4-Acetylantrocamol LT3, a new ubiquinone from Antrodia cinnamomea, inhibits hepatocellular carcinoma HepG2 cell growth by targeting YAP/TAZ, mTOR, and WNT/β-catenin signaling. Am J Chin Med. 48:1243–1261. 2020. View Article : Google Scholar | |
|
Ma L, Jiang H, Xu X, Zhang C, Niu Y, Wang Z, Tao Y, Li Y, Cai F, Zhang X, et al: Tanshinone IIA mediates SMAD7-YAP interaction to inhibit liver cancer growth by inactivating the transforming growth factor beta signaling pathway. Aging (Albany NY). 11:9719–9737. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu H, Li J, Yuan W, Hao S, Wang M, Wang F and Xuan H: Bioactive components and mechanisms of poplar propolis in inhibiting proliferation of human hepatocellular carcinoma HepG2 cells. Biomed Pharmacother. 144:1123642021. View Article : Google Scholar : PubMed/NCBI | |
|
Xu W, Shi Z, Yu X, Xu Y, Chen Y, He Y, Gong Y, Huang C, Tan C and Yang Y: Salvianolic acid B exerts an anti-hepatocellular carcinoma effect by regulating the Hippo/YAP pathway and promoting pSmad3L to pSmad3C simultaneously. Eur J Pharmacol. 939:1754232023. View Article : Google Scholar | |
|
Chang HL, Chen HA, Bamodu OA, Lee KF, Tzeng YM, Lee WH and Tsai JT: Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro. Toxicol In Vitro. 51:74–82. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Jia M, Xiong Y, Li M and Mao Q: Corosolic acid inhibits cancer progress through inactivating YAP in hepatocellular carcinoma. Oncol Res. 28:371–383. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Y, Zhao Y, Guan Y, Guan Y, Zhang X, Chen Y, Wu Q, Zhu G, Chen Y, Sun F, et al: Blocking inhibition to YAP by ActinomycinD enhances anti-tumor efficacy of corosolic acid in treating liver cancer. Cell Signal. 29:209–217. 2017. View Article : Google Scholar | |
|
Wu Q, Liu J, Mao Z, Tian L, Wang N, Wang G, Wang Y and Seto S: Ligustilide attenuates ischemic stroke injury by promoting Drp1-mediated mitochondrial fission via activation of AMPK. Phytomedicine. 95:1538842022. View Article : Google Scholar | |
|
Yang J and Xing Z: Ligustilide counteracts carcinogenesis and hepatocellular carcinoma cell-evoked macrophage M2 polarization by regulating yes-associated protein-mediated interleukin-6 secretion. Exp Biol Med (Maywood). 246:1928–1937. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Song X, Tan L, Wang M, Ren C, Guo C, Yang B, Ren Y, Cao Z, Li Y and Pei J: Myricetin: A review of the most recent research. Biomed Pharmacother. 134:1110172021. View Article : Google Scholar | |
|
Kou JJ, Shi JZ, He YY, Hao JJ, Zhang HY, Luo DM, Song JK, Yan Y, Xie XM, Du GH and Pang XB: Luteolin alleviates cognitive impairment in Alzheimer's disease mouse model via inhibiting endoplasmic reticulum stress-dependent neuroinflammation. Acta Pharmacol Sin. 43:840–849. 2022. View Article : Google Scholar | |
|
Yang N, Chen T, Wang L, Liu R, Niu Y, Sun L, Yao B, Wang Y, Yang W, Liu Q, et al: CXCR4 mediates matrix stiffness-induced downregulation of UBTD1 driving hepatocellular carcinoma progression via YAP signaling pathway. Theranostics. 10:5790–5801. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Xu G, Wang J, Wu F, Wang N, Zhou W, Wang Q, Pan W, Ao G and Yang J: YAP and 14-3-3γ are involved in HS-OA-induced growth inhibition of hepatocellular carcinoma cells: A novel mechanism for hydrogen sulfide releasing oleanolic acid. Oncotarget. 7:52150–52165. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Wang Y, Liu Z, Zhao H, Yao GD, Liu Q and Song SJ: New daphnane diterpenoidal 1,3,4-oxdiazole derivatives as potential anti-hepatoma agents: Synthesis, biological evaluation and molecular modeling studies. Bioorg Chem. 145:1072082024. View Article : Google Scholar : PubMed/NCBI | |
|
Liu K, Wehling L, Wan S, Weiler SME, Tóth M, Ibberson D, Marhenke S, Ali A, Lam M, Guo T, et al: Dynamic YAP expression in the non-parenchymal liver cell compartment controls heterologous cell communication. Cell Mol Life Sci. 81:1152024. View Article : Google Scholar : PubMed/NCBI | |
|
Gao Y, Feng J, Yang G, Zhang S, Liu Y, Bu Y, Sun M, Zhao M, Chen F, Zhang W, et al: Hepatitis B virus X protein-elevated MSL2 modulates hepatitis B virus covalently closed circular DNA by inducing degradation of APOBEC3B to enhance hepatocarcinogenesis. Hepatology. 66:1413–1429. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Fang R, Cui M, Zhang W, Bai X, Wang H, Liu B, Zhang X and Ye L: The oncoprotein HBXIP up-regulates YAP through activation of transcription factor c-Myb to promote growth of liver cancer. Cancer Lett. 385:234–242. 2017. View Article : Google Scholar | |
|
Zhang X, Li Y, Ma Y, Yang L, Wang T, Meng X, Zong Z, Sun X, Hua X and Li H: Yes-associated protein (YAP) binds to HIF-1α and sustains HIF-1α protein stability to promote hepatocellular carcinoma cell glycolysis under hypoxic stress. J Exp Clin Cancer Res. 37:2162018. View Article : Google Scholar | |
|
Liu Y, Ren H, Zhou Y, Shang L, Zhang Y, Yang F and Shi X: The hypoxia conditioned mesenchymal stem cells promote hepatocellular carcinoma progression through YAP mediated lipogenesis reprogramming. J Exp Clin Cancer Res. 38:2282019. View Article : Google Scholar : PubMed/NCBI | |
|
Yan B, Li T, Shen L, Zhou Z, Liu X, Wang X and Sun X: Simultaneous knockdown of YAP and TAZ increases apoptosis of hepatocellular carcinoma cells under hypoxic condition. Biochem Biophys Res Commun. 515:275–281. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Fan W, Adebowale K, Váncza L, Li Y, Rabbi MF, Kunimoto K, Chen D, Mozes G, Chiu DK, Li Y, et al: Matrix viscoelasticity promotes liver cancer progression in the pre-cirrhotic liver. Nature. 626:635–642. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Weiler SME, Bissinger M, Rose F, von Bubnoff F, Lutz T, Ori A, Schirmacher P and Breuhahn K: SEPTIN10-mediated crosstalk between cytoskeletal networks controls mechanotransduction and oncogenic YAP/TAZ signaling. Cancer Lett. 584:2166372024. View Article : Google Scholar : PubMed/NCBI |
